Genetic modification of inflammation and clonal hematopoiesis-associated cardiovascular risk
Zhi YuiD, Trevor P. FidleriD, Yunfeng RuaniD, Caitlyn VlasschaertiD, Tetsushi NakaoiD, Md Mesbah UddiniD, Taralynn MackiD, Abhishek NiroulaiD, Jonathan Brett HeimlichiD, Seyedeh Maryam ZekavatiD, Christopher James GibsoniD, Gabriel Kenneth GriffiniD, Yuxuan WangiD, Gina Marie PelosoiD, Nancy L. Heard‐CostaiD, Daniel A LevyiD, Ramachandran Srini VasaniD, François AguetiD, Kristin ArdlieiD, Kent D. TayloriD, Stephen S. RichiD, Jerome I. RotteriD, Peter LibbyiD, Siddhartha JaiswaliD, Benjamin L. EbertiD, , Pradeep NatarajaniD
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is associated with an increased risk of cardiovascular diseases (CVD), putatively via inflammasome activation. We pursued an inflammatory gene modifier scan for CHIP-associated CVD risk among 424,651 UK Biobank participants. CHIP was identified using whole exome sequencing data of blood DNA and modeled both as a composite and for common drivers (DNMT3A, TET2, ASXL1, and JAK2) separately. We developed predicted gene expression scores for 26 inflammasome-related genes and assessed how they modify CHIP-associated CVD risk. We identify IL1RAP as a potential key molecule for CHIP-associated CVD risk across genes and increased AIM2 gene expression leading to heightened JAK2- and ASXL1-associated CVD risks. We show that CRISPR- induced Asxl1 mutated murine macrophages have a particularly heightened inflammatory response to AIM2 agonism, associated with an increased DNA damage response, as well as increased IL-10 secretion, mirroring a CVD protective effect of IL10 expression in ASXL1 CHIP. Our study supports the role of inflammasomes in CHIP-associated CVD and provides new evidence to support gene-specific strategies to address CHIP-associated CVD risk.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 85
- FWCI
- 17.49
- Field percentile
- top 1%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Monocyte-endothelial interactions as a targetable node in clonal hematopoiesis-mediated cardiovascular disease
Alyssa Parker, Jonathan Brett Heimlich, … Alexander G. Bick·medRxiv·Feb 20, 2024
- CH-related Mutant ASXL1 Promotes Atherosclerosis in Mice via Dysregulated Innate Immunity
Naru Sato, Susumu Goyama, … Toshio Kitamura·Nature Cardiovascular ResearchPeer-reviewed·Dec 9, 2024
- Non-preferential, but detrimental accumulation of macrophages with clonal hematopoiesis-driver mutations in cardiovascular tissues
T.-s. Dederichs, A. Yerdenova, … I. Hilgendorf·bioRxiv·Sep 11, 2023
- Multitargeted Reduction of Inflammation and Atherosclerosis in Tet2-deficient CHIP via XPO1 Inhibition and Atf3 restoration
Nicole Prutsch, Amélie Vromman, … Alfred Thomas Look·bioRxiv·Jun 12, 2025
- Increased CHIP Prevalence Amongst People Living with HIV
Alexander G. Bick, Konstantin Popadin, … S. Yerly·Scientific ReportsPeer-reviewed·Jan 12, 2022
- Clonal Hematopoiesis and Risk of Stroke: Evidence from Over 800,000 Individuals Across Three Cohorts
Kun Zhao, Yash Pershad, … Alexander G. Bick·medRxiv·Oct 22, 2025